
    
      This is a 16-week, Phase II, multi-centre, randomised, double-blind, placebo-controlled,
      parallel group design study in male and female subjects with mild to moderate Alzheimers
      disease (AD). Subjects will undergo 2-week placebo run-in period before randomisation. They
      will undergo weekly review of safety, tolerability and cognitive performance measures.
    
  